For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Zyvox Shows Higher Success Rate than Vancomycin: Pfizer
November 15, 2010
- Kyorin Licenses KRP-203 for IBD to Novartis
November 15, 2010
- Regorafenib's Efficacy Not Dependent on K-RAS Mutation: Bayer
November 15, 2010
- Santen Committed to Recapturing Top Share in Glaucoma Market
November 15, 2010
- Study Group for Developmentof New Adjuvants Created
November 15, 2010
- Takeda's Business to Hit Bottom in FY2013: President Hasegawa
November 15, 2010
- Astellas Acquires Diannexin Assets from Alavita
November 15, 2010
- JPA, JACDS Work to Improve Members' Business Practices
November 15, 2010
- Astellas Expects Additional Sales of ¥56 Bil. from OSI in FY2014
November 15, 2010
- Astellas to Integrate 3 Production Subsidiaries
November 15, 2010
- JMA Opposed to “Healthcare Tourism”
November 15, 2010
- Daiichi Sankyo to Independently Market Memantine
November 15, 2010
- Otsuka Changes Articles of Incorporation
November 15, 2010
- All-Patient Drug Use-Result Survey on Humira Completed
November 15, 2010
- Combined Half-Year Sales of Top-Eight Domestic Firms Up 1.8%
November 15, 2010
- Nippon Kayaku Ties Up with Celltrion to Develop Herceptin, Remicade Biosimilars
November 15, 2010
- Osteoporosis GL to Be Revised in 2011
November 15, 2010
- Astellas: Sales, Profits Down Due to Prograf Patent Expiration
November 15, 2010
- Savings by Generic Substitutionto to Taper Off: Mr Masuhara
November 15, 2010
- GSK Reduces Price of Cervarix by 30% in Canada
November 15, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…